Consensus Genmab A/S Nasdaq

Stocks

GMAB

US3723032062

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 16/10/2026 BST			5-day change	1st Jan Change
37.00 ^USD	-2.17%		-0.19%	+20.13%

10-16	Nordic stocks in North America - Ericsson rose 2.6 percent	FW
10-15	Revolution Medicines' Europe efforts signal solo launch ambitions for cancer drug	RE

b51bb17083f48fa6d56c.c0aClXdeQ4k_FBS449F-IJnmhEN55tmPJnKsrGIY-oQ.QQCy80QIFbFaY23esrgOUviotHsSpJbEEkb19D1OjOE-COP6KCc2zwZ4LA~0411ad8569b3079f1866a90e7079b31c

Analysts' recommendations: Genmab A/S

10-14	UBS Raises Genmab Price Target to DKK 3,100 (2,700), Reiterates Buy	FW
10-13	BNP Paribas raises its price target for Genmab to DKK 2,850 (2,600), reiterates outperform - BN	FW
10-09	BofA 'Bullish' on Genmab's Upcoming Phase 3 Readouts; Buy Rating Maintained	MT
10-09	Deutsche Bank raises price target for Genmab to 3,000 Danish kroner, reiterates buy	FW
10-09	Deutsche Bank raises price target for Genmab to DKK 3,000 (2,750), reiterates buy	FW
10-09	Barclays raises price target for Genmab to DKK 3,100 (2,900), reiterates overweight	FW
10-07	Genmab: Beyond Darzalex
10-07	Deutsche Bank Research Raises Genmab PT, Keeps Buy Rating	MT
10-07	Deutsche Bank reiterates buy on Genmab, raises price target to DKK 2,750	FW
10-07	DNB Carnegie raises price target for Genmab to DKK 2,850 (2,300), reiterates buy	FW
10-06	Bank of America raises target price for Genmab to 2,850 Danish kroner (2,500), reiterates buy	FW
10-06	Deutsche Bank raises price target for Genmab to DKK 2,750 (2,500), reiterates buy	FW
10-06	Genmab in Good Health, Schneider Lacks Energy
10-06	SEB reiterates Buy on Genmab, raises price target to DKK 3,000 (Update)	FW
10-06	SEB raises its price target for Genmab to DKK 3,000 (2,600), reiterates buy	FW
10-06	Barclays: Genmab's Epkinly beats expectations	FW
10-05	Jyske Bank downgrades Genmab to hold (buy), target price DKK2,350 - BN	FW
10-05	Guggenheim Securities raises price target for Genmab's American depositary receipts to $54 (45), reiterates buy	FW
10-05	Jefferies raises price target for Genmab to 2,900 Danish kroner (2,800), reiterates buy	FW
10-05	Barclays sees stronger phase 3 case for Genmab's Rina-S	FW
10-05	SEB raises price target for Genmab to DKK 2,775 (2,600), reiterates buy	FW
09-23	Kempen raises target price for Genmab: 'petosemtamab could be the biggest share-price driver in a decade'	FW
09-08	Barclays raises Genmab price target to 2,900 Danish kroner (2,500), reiterates overweight - BN	FW
09-03	Handelsbanken Adds Xvivo and Vimian as Sector Favorites, Drops Danish Duo	FW
09-01	Deutsche Bank raises price target for Genmab to 2,500 Danish kroner, reiterates buy	FW

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	WUXI APPTEC CO., LTD.					+32.97%
	LONZA GROUP AG					+14.74%
	ARGENX SE					+38.45%
	IQVIA HOLDINGS INC.					+12.07%
	BEONE MEDICINES AG					+18.26%
	REVOLUTION MEDICINES, INC.					+44.87%
	CELLTRION, INC.					+38.06%
	WUXI BIOLOGICS (CAYMAN) INC.					+24.78%
	GENMAB A/S					+8.87%
	Average					+25.90%
	Weighted average by Cap.					+26.76%